Multi-omic Analyses of Plasma Cytokines, Lipidomics, and Transcriptomics Distinguish Treatment Outcomes in Cutaneous Leishmaniasis
Hayna Malta-Santos,
Kiyoshi F. Fukutani,
Carlos A. Sorgi,
Artur T.L. Queiroz,
Viviane Nardini,
Juliana Silva,
Alex Lago,
Lucas P. Carvalho,
Paulo L.R. Machado,
Patrícia T. Bozza,
Jaqueline França-Costa,
Lucia H. Faccioli,
Edgar M. Carvalho,
Bruno B. Andrade,
Valéria M. Borges
Affiliations
Hayna Malta-Santos
Faculdade de Medicina da Bahia (FAMED), Universidade Federal da Bahia, Salvador, Brazil; Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil
Kiyoshi F. Fukutani
Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER), Salvador, Brazil
Carlos A. Sorgi
Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP-USP), Universidade de São Paulo (USP), São Paulo, Brazil
Artur T.L. Queiroz
Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER), Salvador, Brazil
Viviane Nardini
Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP-USP), Universidade de São Paulo (USP), São Paulo, Brazil
Juliana Silva
Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Alex Lago
Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Lucas P. Carvalho
Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Paulo L.R. Machado
Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Patrícia T. Bozza
Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
Jaqueline França-Costa
Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Lucia H. Faccioli
Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP-USP), Universidade de São Paulo (USP), São Paulo, Brazil
Edgar M. Carvalho
Faculdade de Medicina da Bahia (FAMED), Universidade Federal da Bahia, Salvador, Brazil; Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Serviço de Imunologia, C-HUPES, Universidade Federal da Bahia, Salvador, Brazil
Bruno B. Andrade
Faculdade de Medicina da Bahia (FAMED), Universidade Federal da Bahia, Salvador, Brazil; Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER), Salvador, Brazil; Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil; Universidade Salvador (UNIFACS), Laureate Universities, Salvador, Brazil; Corresponding author
Valéria M. Borges
Faculdade de Medicina da Bahia (FAMED), Universidade Federal da Bahia, Salvador, Brazil; Instituto Gonçalo Moniz (IGM), Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Brazil; Corresponding author
Summary: Leishmania braziliensis infection frequently results in cutaneous leishmaniasis (CL). An increase in incidence of drug-resistant CL leading to treatment failure has been reported. Identification of reliable predictors of treatment outcomes is necessary to optimize patient care. Here, we performed a prospective case-control study in which plasma levels of cytokines and lipid mediators were assessed at different time points during antileishmanial therapy in patients with CL from Brazil. Multidimensional analyses were employed to describe a combination of biomarkers able to predict and characterize treatment failure. We found a biosignature influenced mainly by plasma levels of lipid mediators that accurately predicted treatment failure. Furthermore, transcriptomic analysis of a publicly available data set revealed that expression levels of genes related to lipid metabolism measured in skin lesions could distinguish treatment outcomes in CL. Thus, activation of pathways linked to lipid biosynthesis predicts treatment failure in CL. The biomarkers identified may be further explored as therapeutic targets.